Trump attacks “slow and burdensome” drug approval process, triggering a pitch from Amicus CEO
President Donald Trump outlined his political agenda for 2017 in his address to a joint session of Congress Tuesday night, aiming a broadside directed straight at the “burdensome” drug approval process at the FDA. And a prominent CEO in the rare disease field stepped into Trump’s high powered spotlight to urge a change in the way the agency handles orphan drugs while making a pitch for a speedy reversal of a painful setback handed to him by regulators last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.